Free Trial

Disc Medicine (IRON) Stock Price, News & Analysis

Disc Medicine logo
$47.13
+2.31 (+5.15%)
(As of 11/1/2024 ET)

About Disc Medicine Stock (NASDAQ:IRON)

Key Stats

Today's Range
$45.02
$47.16
50-Day Range
$44.82
$52.73
52-Week Range
$25.60
$77.60
Volume
212,328 shs
Average Volume
344,315 shs
Market Capitalization
$1.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.40
Consensus Rating
Moderate Buy

Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Disc Medicine Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
75th Percentile Overall Score

IRON MarketRank™: 

Disc Medicine scored higher than 75% of companies evaluated by MarketBeat, and ranked 281st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Disc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Disc Medicine has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Disc Medicine's stock forecast and price target.
  • Earnings Growth

    Earnings for Disc Medicine are expected to decrease in the coming year, from ($4.09) to ($4.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Disc Medicine is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Disc Medicine is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Disc Medicine has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Disc Medicine's valuation and earnings.
  • Percentage of Shares Shorted

    9.54% of the float of Disc Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Disc Medicine has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Disc Medicine has recently decreased by 6.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Disc Medicine does not currently pay a dividend.

  • Dividend Growth

    Disc Medicine does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.54% of the float of Disc Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Disc Medicine has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Disc Medicine has recently decreased by 6.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Disc Medicine has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Disc Medicine this week, compared to 4 articles on an average week.
  • Search Interest

    15 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,313.00 in company stock.

  • Percentage Held by Insiders

    Only 4.24% of the stock of Disc Medicine is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Disc Medicine's insider trading history.
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

IRON Stock News Headlines

We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Drops By 6.9%
Disc Medicine's (IRON) Buy Rating Reaffirmed at HC Wainwright
Disc Medicine’s Promising Anemia Treatment Drives Buy Rating
See More Headlines

IRON Stock Analysis - Frequently Asked Questions

Disc Medicine's stock was trading at $57.76 on January 1st, 2024. Since then, IRON shares have decreased by 18.4% and is now trading at $47.13.
View the best growth stocks for 2024 here
.

Disc Medicine, Inc. (NASDAQ:IRON) released its quarterly earnings results on Thursday, August, 8th. The company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.08.

Top institutional shareholders of Disc Medicine include China Universal Asset Management Co. Ltd. (0.02%), SG Americas Securities LLC (0.02%) and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Brian Richard Macdonald, Joanne Bryce, Mona Ashiya, Rahul Khara and William Jacob Savage.
View institutional ownership trends
.

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

Last Earnings
8/08/2024
Today
11/02/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IRON
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$66.40
High Stock Price Target
$89.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+40.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-76,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.17 per share

Miscellaneous

Free Float
28,466,000
Market Cap
$1.40 billion
Optionable
Not Optionable
Beta
0.59
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:IRON) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners